Noticias y Actividades de Kodiak Sciences

Kodiak Sciences es una de las ...

• Russell 3000;
• TOB Iconic 10,000.

Kodiak Sciences es una empresa que cotiza bajo el símbolo de cotización KOD (US).

Ver el organigrama con sus 19 ejecutivos principales

Biografías más buscadas en Kodiak Sciences

• Victor Perlroth, Chairman and Chief Executive Officer
• Charles Bancroft, Director
• Taiyin Yang, Director

Crear su alerta
para seguir los movimientos de los ejecutivos en Kodiak Sciences.

Kodiak Sciences tiene 2.350 competidores entre los que se incluyen Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) y Lonza (Suiza).

Popular M&A news in Biotecnología

• Sirius Therapeutics acaba de anunciar una recaudación de fondos de 50 millones de dólares. (publicado el 16 de junio de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado el 12 de junio de 2025).
• SpliceBio acaba de anunciar una recaudación de fondos de 135 millones de dólares. (publicado el 11 de junio de 2025).

Otros contactos sugeridos en el sector Biotecnología

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships en WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board en Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization en Wheeler Bio

Saber más sobre el sector Biotecnología

Últimos comunicados de prensa de Kodiak Sciences

• Kodiak Sciences Treats First Patients in Three Phase 3 Studies of KSI-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion | Kodiak Sciences Inc.
• Kodiak Sciences to Present at Upcoming Conferences | Kodiak Sciences Inc.
• Kodiak Sciences Announces Second Quarter 2020 Financial Results and Recent Business Highlights | Kodiak Sciences Inc.
• Lonza's Ibex Dedicate to Support the Commercial Manufacture of Kodiak’s KSI-301 - an Antibody Biopolymer Conjugate for Retinal Diseases | Kodiak Sciences Inc.
• Kodiak Sciences to Host R&D Webcast to Review Recent Data from the Ongoing Phase 1b Study of KSI-301 and Highlight KSI-301 Clinical Development Progress | Kodiak Sciences Inc.
• Kodiak Sciences Announces New Longer-Term Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Society of Retin
• Kodiak Sciences Announces Upcoming Presentation of KSI-301 Clinical Study Data at American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting and R&D Webinar | Kodiak Sciences Inc.
• Kodiak Sciences to Present at Upcoming Conferences | Kodiak Sciences Inc.
• Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference | Kodiak Sciences Inc.
• Kodiak Sciences Announces First Quarter 2020 Financial Results and Recent Business Highlights | Kodiak Sciences Inc.
• View more press releases Close

Redes sociales sobre Kodiak Sciences

• Kodiak Sciences en Wikipedia, Google News y Yahoo Finance
• Kodiak Sciences en LinkedIn, Twitter y YouTube